- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What You May Have Missed at Asembia 2023
The 2023 Asembia Specialty Pharmacy Summit took place in early May in Las Vegas, Nevada, and The American Journal of Managed Care® was there to cover the meeting—catch up on what you may have missed.
Here are the top stories from the 2023 Asembia Specialty Pharmacy Summit, which took place April 30 to May 4 in Las Vegas, Nevada.
An Overview of the Specialty Therapy Pipeline in 2023
At the first business session of Asembia 2023, Ray Tancredi, divisional vice president at Walgreens, provided updates to the 2023 specialty therapy pipeline.
Dr Fran Gregory Discusses the Implications of a New Wave of Biosimilars
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses what's to come as a result of a “second wave” of biosimilars hitting the market.
Survey Shows Payers More Likely to Prefer Multiple Biosimilars for the Same Reference Product
Speakers presented on the payer perspective regarding biosimilars, including that they feel comfortable preferring multiple biosimilars for the same reference product and are looking for interchangeability designations.
Payers, Drug Manufacturers Can Expect More Liability Under New IRA Drug Pricing Policies
Panelists at Asembia 2023 discussed the myriad of ways that the drug pricing policies of the Inflation Reduction Act (IRA), such as inflation rebates and a redesign of Medicare Part D plans, will affect payers and manufacturers.
How Health Care Institutions Can Leverage Biosimilars to Generate Savings
August 17th 2022On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.
Listen
Navigating the Biosimilar Frontier: Opportunities and Challenges in 2024
January 14th 2024Biosimilars offer substantial promise for a new era of accessibility and affordability for patients and the broader health care industry, but better understanding of these products from payers and providers is necessary for biosimilars to reach their full potential in the US.
Read More
